Calcium channel blockers for primary and secondary Raynaud's phenomenon.

CONCLUSIONS: Randomized controlled trials with evidence of low to moderate quality showed that CCBs (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, pain and disability associated with Raynaud's phenomenon. Higher doses may be more effective than lower doses and these CCBs may be more effective in primary RP. Although there were more withdrawals due to adverse events in the treatment groups, no serious adverse events were reported.
PMID: 29237099 [PubMed - as supplied by publisher]

Source: Cochrane Database of Systematic Reviews - December 13, 2017 Category: General Medicine Authors: Rirash F, Tingey PC, Harding SE, Maxwell LJ, Tanjong Ghogomu E, Wells GA, Tugwell P, Pope J Tags: Cochrane Database Syst Rev Source Type: research